… While this classical genomic dependency is relevant to most cancers, breast and prostate
cancers are unique in their well-established additional dependence on hormone receptor (HR) …

… Increasing numbers of targeted drugs are used in hormone receptor … therapy. This study
will systemically review the progress made in endocrine therapy combined with targeted therapy …

… To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-…
receptor 2 (HER2)-negative, PIK3CA-mutated, ABC, or MBC following prior endocrine therapy …

… therapy is not uncommon. Over the past decades, the emergence of novel targeted therapy
in combination with endocrine therapy … This paper reviews available data of targeted therapy …

… in patients with hormone receptor (HR) positive, HER2 negative disease. Endocrine therapy
(ET… generation of targeted therapies for advanced breast cancer. In addition to anti-estrogen …

… However, the possibility of altered tumour characteristics with a switch of hormone receptor
(… endocrine therapy is the treatment of choice for patients with an advanced hormone receptor-…

… This review will compare the available endocrine therapy and targeted therapy options for
HR-positive/HER2-negative ABC in postmenopausal women, with some mention of treatment …

… of nonendocrine agents for patients with hormone receptor–positive but HER2-negative
metastatic breast cancer who are no longer benefiting from endocrine therapy (with or without …

… non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival
(PFS) and overall survival (OS) in receptor-… on targeted and comparator therapy, receptor …

… Although major advances in our understanding of the molecular underpinnings of hormone
receptor–positive (HR + ) breast cancer have led to new therapies that have substantially …